Literature DB >> 23921444

Targeted antifungal prophylaxis in heart transplant recipients.

Patricia Muñoz1, Maricela Valerio, Jesús Palomo, Maddalena Giannella, Juan F Yañez, Manuel Desco, Emilio Bouza.   

Abstract

BACKGROUND: Antifungal prophylaxis after heart transplantation is usually targeted to high-risk recipients, but the duration is normally fixed and empirical. Our purpose was to assess the efficacy of a personalized prophylactic approach based on the duration of the risk factors.
METHODS: In a prospective cohort, from 2003 to 2010, prophylaxis was only administered to patients with risk factors (13 of 133) and duration was personalized, starting with the risk factor and continued a median of 20 days after its resolution.
RESULTS: Antifungal prophylaxis was prescribed only in 9.8% of the recipients and was effective in all but one patient who should have received a higher dose of caspofungin due to his obesity. Despite suffering an outbreak of invasive aspergillosis (IA) in the intensive care unit due to extremely high concentration of spores in the air (three cases with no personal risk factors), there was a reduction in the incidence of IA (8.6% vs. 2.2%; P=0.01) and Aspergillus-related mortality (5.75% vs. 1.5%; P=0.06).
CONCLUSIONS: Targeted prophylaxis for IA in heart recipients provided only to patients with risk factors and maintained for a median of 20 days after their disappearance is effective and safe. A high environmental load of Aspergillus spores in the intensive care unit would also indicate the need for antifungal prophylaxis in all exposed patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921444     DOI: 10.1097/TP.0b013e31829e6d7b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Personalized treatment in heart transplantation.

Authors:  Kiran K Khush
Journal:  Curr Opin Organ Transplant       Date:  2017-06       Impact factor: 2.640

2.  Risk factors for invasive fungal disease in heart transplant recipients.

Authors:  Alexander S Rabin; Michael M Givertz; Gregory S Couper; Margaret M Shea; Driele Peixoto; Deborah S Yokoe; Lindsey R Baden; Francisco M Marty; Sophia Koo
Journal:  J Heart Lung Transplant       Date:  2014-10-02       Impact factor: 10.247

3.  Case of Renal Aspergillosis after Heart Transplant: Diagnosis and Treatment.

Authors:  M Mahdavi; G Mortaz-Hejri; H Shahzadi; H R Pouraliakbar; A Amin; M Hesami; B Naghavi
Journal:  Int J Organ Transplant Med       Date:  2021

4.  Population Pharmacokinetics of Caspofungin and Dose Simulations in Heart Transplant Recipients.

Authors:  Zheng Wu; Jinhua Lan; Xipei Wang; Yijin Wu; Fen Yao; Yifan Wang; Bo-Xin Zhao; Yirong Wang; Jingchun Chen; Chunbo Chen
Journal:  Antimicrob Agents Chemother       Date:  2022-04-07       Impact factor: 5.938

5.  Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response.

Authors:  Dionysios Neofytos; Carolina Garcia-Vidal; Frédéric Lamoth; Christoph Lichtenstern; Alessandro Perrella; Jörg Janne Vehreschild
Journal:  BMC Infect Dis       Date:  2021-03-24       Impact factor: 3.090

6.  Fatal Case of Probable Invasive Aspergillosis after Five Years of Heart Transplant: A Case Report and Review of the Literature.

Authors:  Toufik Mahfood Haddad; Mahesh Anantha Narayanan; Krista E Shaw; Renuga Vivekanandan
Journal:  Case Rep Infect Dis       Date:  2015-08-24

7.  International Air Travel to Ohio, USA, and the Impact on Malaria, Influenza, and Hepatitis A.

Authors:  Donald E Brannen; Ali Alhammad; Melissa Branum; Amy Schmitt
Journal:  Scientifica (Cairo)       Date:  2016-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.